WAVE Life Sciences (WVE) Competitors

$6.96 -0.11 (-1.49%)

As of 01:09 PM Eastern

WVE vs. GRFS, RYTM, LNTH, SRRK, and IMVT

Should you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Scholar Rock (SRRK), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does WAVE Life Sciences compare to Grifols?

WAVE Life Sciences (NASDAQ:WVE) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

WAVE Life Sciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, Grifols has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Grifols had 4 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Grifols and 3 mentions for WAVE Life Sciences. Grifols' average media sentiment score of 0.95 beat WAVE Life Sciences' score of 0.92 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to WAVE Life Sciences' net margin of -255.70%. Grifols' return on equity of 6.21% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Grifols	5.54%	6.21%	2.39%

89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Grifols has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	31.36	-$204.38M	-$1.06	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.08

WAVE Life Sciences currently has a consensus target price of $27.50, indicating a potential upside of 294.83%. Grifols has a consensus target price of $10.00, indicating a potential upside of 31.32%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe WAVE Life Sciences is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Grifols beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, indicating a potential upside of 46.32%. WAVE Life Sciences has a consensus target price of $27.50, indicating a potential upside of 294.83%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

In the previous week, Rhythm Pharmaceuticals had 16 more articles in the media than WAVE Life Sciences. MarketBeat recorded 19 mentions for Rhythm Pharmaceuticals and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.92 beat Rhythm Pharmaceuticals' score of 0.66 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Rhythm Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.53	-$196.54M	-$3.13	N/A
WAVE Life Sciences	$42.73M	31.36	-$204.38M	-$1.06	N/A

89.7% of WAVE Life Sciences shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Summary

WAVE Life Sciences beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Lantheus presently has a consensus target price of $99.71, indicating a potential upside of 6.08%. WAVE Life Sciences has a consensus target price of $27.50, indicating a potential upside of 294.83%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

In the previous week, Lantheus had 21 more articles in the media than WAVE Life Sciences. MarketBeat recorded 24 mentions for Lantheus and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.92 beat Lantheus' score of 0.63 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to WAVE Life Sciences' net margin of -255.70%. Lantheus' return on equity of 29.32% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Lantheus has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	3.97	$233.56M	$4.15	22.65
WAVE Life Sciences	$42.73M	31.36	-$204.38M	-$1.06	N/A

99.1% of Lantheus shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Summary

Lantheus beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Scholar Rock?

WAVE Life Sciences (NASDAQ:WVE) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, Scholar Rock had 22 more articles in the media than WAVE Life Sciences. MarketBeat recorded 25 mentions for Scholar Rock and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.92 beat Scholar Rock's score of 0.76 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	31.36	-$204.38M	-$1.06	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Scholar Rock	N/A	-169.41%	-106.07%

WAVE Life Sciences currently has a consensus target price of $27.50, indicating a potential upside of 294.83%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 15.72%. Given WAVE Life Sciences' higher probable upside, research analysts clearly believe WAVE Life Sciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

WAVE Life Sciences beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Immunovant?

Immunovant (NASDAQ:IMVT) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Immunovant has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market.

WAVE Life Sciences has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A
WAVE Life Sciences	$42.73M	31.36	-$204.38M	-$1.06	N/A

In the previous week, Immunovant and Immunovant both had 3 articles in the media. Immunovant's average media sentiment score of 1.19 beat WAVE Life Sciences' score of 0.92 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-63.17%	-58.01%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Immunovant presently has a consensus price target of $32.44, suggesting a potential upside of 15.08%. WAVE Life Sciences has a consensus price target of $27.50, suggesting a potential upside of 294.83%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats Immunovant on 11 of the 14 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.34B	$3.41B	$6.28B	$12.04B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-6.55	15.30	20.49	25.22
Price / Sales	31.36	299.37	544.52	74.60
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	2.25	6.77	9.58	6.58
Net Income	-$204.38M	$24.11M	$3.55B	$333.40M
7 Day Performance	-2.99%	-2.32%	-0.82%	-0.99%
1 Month Performance	-2.99%	3.01%	5.46%	7.15%
1 Year Performance	5.53%	69.45%	37.70%	34.19%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	3.0405 of 5 stars	$6.97 -1.5%	$27.50 +294.8%	+7.3%	$1.34B	$42.73M	N/A	240
GRFS Grifols	4.5878 of 5 stars	$8.23 -0.1%	$10.00 +21.5%	+9.1%	$5.60B	$8.51B	43.32	23,822	News Coverage Analyst Upgrade
RYTM Rhythm Pharmaceuticals	2.4934 of 5 stars	$81.81 +0.6%	$131.13 +60.3%	+52.3%	$5.59B	$189.76M	N/A	140	Earnings Report Analyst Upgrade Analyst Revision
LNTH Lantheus	2.851 of 5 stars	$85.50 +1.0%	$88.86 +3.9%	+14.9%	$5.57B	$1.54B	25.37	1,193	Earnings Report Analyst Downgrade
SRRK Scholar Rock	2.4649 of 5 stars	$46.37 -0.5%	$55.40 +19.5%	+56.7%	$5.53B	N/A	N/A	140	Trending News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. GRFS, RYTM, LNTH, SRRK, and IMVT

How does WAVE Life Sciences compare to Grifols?

Summary

How does WAVE Life Sciences compare to Rhythm Pharmaceuticals?

Summary

How does WAVE Life Sciences compare to Lantheus?

Summary

How does WAVE Life Sciences compare to Scholar Rock?

Summary

How does WAVE Life Sciences compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. GRFS, RYTM, LNTH, SRRK, and IMVT

How does WAVE Life Sciences compare to Grifols?

Which has more risk and volatility, WVE or GRFS?

Does the media prefer WVE or GRFS?

Is WVE or GRFS more profitable?

Do institutionals and insiders believe in WVE or GRFS?

Which has stronger earnings and valuation, WVE or GRFS?

Do analysts prefer WVE or GRFS?

Summary

How does WAVE Life Sciences compare to Rhythm Pharmaceuticals?

Do analysts recommend RYTM or WVE?

Does the media favor RYTM or WVE?

Is RYTM or WVE more profitable?

Which has better valuation & earnings, RYTM or WVE?

Do institutionals & insiders believe in RYTM or WVE?

Which has more risk and volatility, RYTM or WVE?

Summary

How does WAVE Life Sciences compare to Lantheus?

Do analysts recommend LNTH or WVE?

Does the media favor LNTH or WVE?

Is LNTH or WVE more profitable?

Which has better valuation & earnings, LNTH or WVE?

Do institutionals & insiders believe in LNTH or WVE?

Which has more risk and volatility, LNTH or WVE?

Summary

How does WAVE Life Sciences compare to Scholar Rock?

Which has more volatility & risk, WVE or SRRK?

Does the media prefer WVE or SRRK?

Which has preferable earnings & valuation, WVE or SRRK?

Is WVE or SRRK more profitable?

Do analysts rate WVE or SRRK?

Do institutionals and insiders have more ownership in WVE or SRRK?

Summary

How does WAVE Life Sciences compare to Immunovant?

Which has more risk & volatility, IMVT or WVE?

Which has stronger valuation and earnings, IMVT or WVE?

Does the media refer more to IMVT or WVE?

Do institutionals & insiders have more ownership in IMVT or WVE?

Is IMVT or WVE more profitable?

Do analysts rate IMVT or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools